SCHEMBL25545944

SCHEMBL25545944

COc1cc(OC)cc(-c2nc(Cl)sc2CC(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 1/20 0.44
CYP1A1 P04798 5/20 0.38
CYP1B1 Q16678 5/20 0.38
CYP1A2 P05177 2/20 0.37
CYP2E1 P05181 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C8 P10632 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2A6 P11509 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP4B1 P13584 2/20 0.37
CYP2B6 P20813 2/20 0.37
CYP3A5 P20815 2/20 0.37
CYP2A7 P20853 2/20 0.37
CYP3A7 P24462 2/20 0.37
CYP2F1 P24903 2/20 0.37
CYP2C18 P33260 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP2J2 P51589 2/20 0.37
CYP4F2 P78329 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25546332 0.92 FBP1 (0.41) FBP1CYP1A1CYP1B1CYP1A2CYP2E1
SCHEMBL25546318 0.88 FBP1 (0.38) FBP1ADORA2AADORA1KMT2AMEN1
SCHEMBL25545933 0.87 TDP1 (0.44) FBP1ADORA2AADORA1SMN1; SMN2KDM4E
SCHEMBL25556546 0.84 FBP1 (0.42) FBP1CYP1A1CYP1B1CYP1A2CYP2E1
SCHEMBL25545941 0.80 LMNA (0.48) FBP1KMT2AMEN1SMN1; SMN2KDM4E
SCHEMBL25545928 0.79 FBP1 (0.42) FBP1KMT2AMEN1ALDH1A1L3MBTL1
SCHEMBL25546362 0.79 FBP1 (0.42) FBP1KMT2AMEN1
SCHEMBL25545932 0.79 FBP1 (0.44) FBP1KDM4EALDH1A1TDP1LMNA
SCHEMBL25546361 0.78 FBP1 (0.43) FBP1KMT2AMEN1LMNAMAPT
SCHEMBL25546325 0.78 S1PR1 (0.50) FBP1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 FBP1 735/4885CYP1A1 4849/4885CYP1B1 4728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.